| abstract |
Provided is a pharmaceutical product for avoiding or reducing poisoning caused by LCT (= large clostridial cytotoxin). A pharmaceutical comprising at least one effector, ie inhibitor or activator, of the protease activity of LCT (Large Clostridial Cytotoxin) as an active substance. The agent is a protease activity of Clostridial difficile toxin A (TcdA) and / or Clostridial difficile toxin B (TcdB) and / or Clostridial soldery lathere toxin (TcsL) and / or Clostridial novi α-toxin (Tcnα) An effector, ie an inhibitor or activator. The inhibitor is 1,2-epoxy-3- (p-nitrophenoxy) -propane (EPNP). The activator is inositol phosphate, preferably inositol hexaphosphate (IP6). [Selection figure] None |